Are Two CGRP Blockers Better Than One? Evaluating Dual Anti-CGRP Therapy for Chronic Migraine | Research

The takeaway

Dual CGRP pathway antagonism (combining anti-CGRP antibodies with gepants or different anti-CGRP mechanisms) shows potential for chronic migraine, particularly in patients who partially respond to monotherapy.

Two targets, one pathway
Combining anti-CGRP antibodies with gepants could provide more complete CGRP pathway blockade for resistant migraine

What the researchers found

Dual CGRP pathway antagonism shows potential for chronic migraine through complementary mechanisms, with emerging evidence supporting combination anti-CGRP antibody + gepant approaches in partial responders.

Why it matters

Up to 50% of chronic migraine patients don't adequately respond to single anti-CGRP therapy. Dual targeting could help these patients.

How the study worked

Review evaluating the rationale, evidence, and safety considerations for dual CGRP antagonism in chronic migraine treatment.

What this study cannot tell us

Limited clinical evidence for dual approaches. Safety of combining CGRP blockers unknown. Cost implications significant.

How to read the evidence

Review of emerging evidence. Strong mechanistic rationale but limited clinical data for combination approaches.

When this study was published

Published in 2025.

The bigger picture

Dual CGRP targeting parallels the evolution in oncology where combination therapies often outperform monotherapy by targeting multiple nodes in a pathway.

Questions still open

What is the optimal combination of anti-CGRP agents?
Is there a safety ceiling for CGRP pathway blockade?
Which patients would benefit most from dual therapy?

Common questions

Can I take two CGRP blockers for migraines?

Emerging evidence suggests combining different types of CGRP blockers (like an antibody injection with an oral gepant) might help patients who partially respond to one alone. Discuss with your neurologist.

Is it safe to block CGRP from two directions?

The safety of dual CGRP blockade is still being studied. CGRP has protective functions in the body, so the safety ceiling for pathway suppression needs careful evaluation.

Read the original research

Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.

Headache

View on PubMed ↗Publisher’s paper ↗

Citation

Graves, Kara S; To, Jason; Paige, Hayley; Kennedy, Amanda G; Sprouse-Blum, Adam S; Devine, Derek; MacDougall, Julie. (2026). Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.. Headache. https://doi.org/10.1111/head.70057